Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

NCT06025851 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Anti-human CCL24 monoclonal antibody (CM-101)
DRUG: Placebo

Sponsor

ChemomAb Ltd.